ReviewAntibiotics (Basel, Switzerland)2026
Resistance to Linezolid and Pretomanid in the Era of Modern Drug-Resistant Tuberculosis Treatment in South Africa: A Systematic Review and Meta-Analysis.
Review in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe success of modern drug-resistant tuberculosis (DR-TB) regimens increasingly depends on linezolid (LZD) and pretomanid (Pa), yet the emergence of resistance to these critical agents threatens to reverse recent treatment advances, with limited consolidated evidence available from high-burden settings such as South Africa.
objectivesTo systematically review and meta-analyse South African data on LZD and Pa resistance, minimum inhibitory concentrations (MICs), resistance-associated mutations, and treatment outcomes. ELIGIBILITY CRITERIA: We included clinical trials, cohort studies, surveillance studies, and molecular investigations conducted in South Africa from 2013 onward that reported resistance prevalence, MIC data, genotypic mutations, or treatment outcomes related to LZD and/or Pa. INFORMATION SOURCES: PubMed, PubMed, Embase, Web of Science, and grey literature sources were searched from January 2013 to 31 December 2025 in accordance with PRISMA 2020 guidelines. Risk of Bias: Study quality was assessed using the Joanna Briggs Institute (JBI) cohort appraisal checklist. INCLUDED STUDIES: Seventeen studies representing provincial and national cohorts were included. SYNTHESIS OF
resultsRandom-effects meta-analysis was used to estimate pooled baseline resistance. Subgroup, sensitivity, and meta-regression analyses were performed.
resultsRandom-effects meta-analysis demonstrated a pooled baseline LZD resistance prevalence of 0.53% (95% CI: 0.01-1.83; I LIMITATIONS: Limited study numbers, heterogeneity in laboratory methods, and overrepresentation of certain provinces may affect generalizability.
conclusionsBaseline resistance to LZD and Pa in South Africa remains low, supporting continued programmatic use. Ongoing molecular surveillance is essential to detect resistance amplification and preserve regimen efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.